Zombie Spine company of the week.

Congratulations to Implanet !

Implanet, founded in 2007 and based in Bordeaux, France. The company’s flagship products include the JAZZ® spinal implant, which is designed to enhance spinal fusion procedures, and the MADISON knee implant.

In 2023, Implant’s gross sales are $8M in annual sales and lost -$8M in earnings. In other words, it cost Implanet $16M to make $8M in sales. Seven years after their IPO, their market cap is worth $14M.

They have no financial leverage. They cannot go public again.

Seriously, you and I could do better by opening up a donut shop.

OrthoWorld shared the newest FDA clearance from Implant below…

Implanet announced FDA 510(k) clearance to market its new hybrid fixation system Jazz Spinal System.

As a result of the technological partnership established in 2022 with Sanyou Medical, this Jazz Spinal System features a comprehensive solution of pedicle screws, combined with the JAZZ Band implant range. Jazz Spinal System includes a complete system for the treatment of pediatric deformity as well as a comprehensive range of solutions for treating adult spinal pathologies, including minimally invasive approaches. Designed for both traditional open surgery of the thoracolumbar spine and minimally invasive percutaneous fixation, this system also meets the needs of surgeons treating complex deformities.

Ludovic Lastennet, Implanet’s CEO, said, “Following the technological partnership signed two years ago, we are proud to announce the clearance of a groundbreaking and innovative hybrid fixation system Jazz Spinal System in the United States. This milestone demonstrates the full potential of the synergies provided by our partnership with Sanyou Medical. Implanet America’s sales teams, revitalized by the implementation of new management at the beginning of the year, will be able to launch the commercialization of this new solution during the summer of 2024. This represents a significant milestone in our development plan in the United States, the leading market for spinal surgery globally, aimed at strengthening our offering in this strategic market.”